- $2.25m
- -$3.19m
- $0.07m
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
NASDAQ RESUMED AT 09:30 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 06:22 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Silo Pharma’S Ptsd Program Advances As FDA Fast-Tracks Psychedelic Therapies For Ptsd
Brief: Silo Pharma Announces Share Buyback Program
Brief: Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd
Brief: Silo Pharma Selects Alphaledger’S T12 Fund For Tokenized Real-World Asset Investments On Solana Blockchain
Brief: Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Brief: Silo Pharma Announces Initial Purchase Of Bitcoin
Brief: Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market
Brief: Silo Pharma Updates Strategic Agreement With Fireblocks To Secure Crypto Treasury Management
Brief: Silo Pharma Announces Initial Investment In Ethereum And Solana Under Cryptocurrency Treasury Strategy
Brief: Silo Pharma Secures Australian Patent Covering Licensed Ptsd Drug Candidate Expanding Global Ip Portfolio
Brief: Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics